WO2012102937A3 - Benz imidazole compounds that expand hematopoietic stem cells - Google Patents

Benz imidazole compounds that expand hematopoietic stem cells Download PDF

Info

Publication number
WO2012102937A3
WO2012102937A3 PCT/US2012/021898 US2012021898W WO2012102937A3 WO 2012102937 A3 WO2012102937 A3 WO 2012102937A3 US 2012021898 W US2012021898 W US 2012021898W WO 2012102937 A3 WO2012102937 A3 WO 2012102937A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
hematopoietic stem
imidazole compounds
benz imidazole
expand hematopoietic
Prior art date
Application number
PCT/US2012/021898
Other languages
French (fr)
Other versions
WO2012102937A2 (en
Inventor
Laure Christina BOUCHEZ
Anthony E. Boitano
Michael P. Cooke
Peter G. Schultz
Original Assignee
Irm Llc
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, The Scripps Research Institute filed Critical Irm Llc
Publication of WO2012102937A2 publication Critical patent/WO2012102937A2/en
Publication of WO2012102937A3 publication Critical patent/WO2012102937A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.
PCT/US2012/021898 2011-01-25 2012-01-19 Compounds that expand hematopoietic stem cells WO2012102937A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161436025P 2011-01-25 2011-01-25
US61/436,025 2011-01-25

Publications (2)

Publication Number Publication Date
WO2012102937A2 WO2012102937A2 (en) 2012-08-02
WO2012102937A3 true WO2012102937A3 (en) 2012-11-29

Family

ID=45562464

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/021898 WO2012102937A2 (en) 2011-01-25 2012-01-19 Compounds that expand hematopoietic stem cells

Country Status (1)

Country Link
WO (1) WO2012102937A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503833A (en) * 2014-01-23 2017-02-02 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Ikariin derivatives
US20170362184A1 (en) * 2014-12-11 2017-12-21 University Court Of The University Of Glasgow Pro-survival compounds
JP7278945B2 (en) * 2016-09-20 2023-05-22 サントル レオン ベラール Benzimidazole derivatives as anticancer agents
IL248028B (en) * 2016-09-25 2022-02-01 Univ Bar Ilan Wasp-protecting small molecules, compositions, methods and uses thereof in the treatment of wiskott-aldrich syndrome and x-linked thrombocytopenia
WO2018167317A1 (en) * 2017-03-17 2018-09-20 Universität Zürich Method for in-vitro stem cell expansion
SG11202102208WA (en) * 2018-09-04 2021-04-29 Magenta Therapeutics Inc Aryl hydrocarbon receptor antagonists and methods of use
EP4265246A1 (en) * 2022-04-22 2023-10-25 Université Paris Cité Compounds inducing production of proteins by immune cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024174A1 (en) * 2004-09-03 2006-03-09 Prometic Biosciences Inc. Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
WO2008073748A1 (en) * 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
WO2009019504A1 (en) * 2007-08-03 2009-02-12 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2009155362A1 (en) * 2008-06-19 2009-12-23 Ligand Pharmaceuticals Inc. Small molecule hematopoietic growth factor mimetic compounds and their uses
WO2010034796A1 (en) * 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh 1h-benz imidazole-5-carboxamides as anti-inflammatory agents
WO2010059401A2 (en) * 2008-10-30 2010-05-27 Irm Llc Compounds that expand hematopoietic stem cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002529502A (en) 1998-11-17 2002-09-10 スミスクライン・ビーチャム・コーポレイション Treatment of thrombocytopenia
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
AU4692400A (en) 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
ES2256038T3 (en) 1999-09-10 2006-07-16 Smithkline Beecham Corporation THROMBOPOYETINE MIMETICS.
US6552008B1 (en) 1999-09-24 2003-04-22 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1228051A1 (en) 1999-11-05 2002-08-07 SmithKline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
DE60031714T2 (en) 1999-12-06 2007-09-06 Smithkline Beecham Corp. Thrombopoietin mimetics
CY2010012I2 (en) 2000-05-25 2020-05-29 Novartis Ag THROMBOPOIETIN MIMETICS
US7241783B2 (en) 2000-12-19 2007-07-10 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2002085343A1 (en) 2001-03-01 2002-10-31 Smithkline Beecham Corporation Thrombopoietin mimetics
AU2003248630A1 (en) 2002-06-06 2003-12-22 Smithkline Beecham Corporation Thrombopoietin mimetics
US20060084682A1 (en) 2002-12-13 2006-04-20 Heerding Dirk A Thrombopoietin mimetics
CN101213190A (en) 2005-07-14 2008-07-02 Irm责任有限公司 Compounds and compositions as TPO mimetics
AU2006279537A1 (en) 2005-08-15 2007-02-22 Irm Llc Compounds and compositions as TPO mimetics
KR20090021217A (en) 2006-06-14 2009-02-27 추가이 세이야쿠 가부시키가이샤 Hematopoietic stem cell proliferation promoter
WO2008028645A1 (en) 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024174A1 (en) * 2004-09-03 2006-03-09 Prometic Biosciences Inc. Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
WO2008073748A1 (en) * 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
WO2009019504A1 (en) * 2007-08-03 2009-02-12 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2009155362A1 (en) * 2008-06-19 2009-12-23 Ligand Pharmaceuticals Inc. Small molecule hematopoietic growth factor mimetic compounds and their uses
WO2010034796A1 (en) * 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh 1h-benz imidazole-5-carboxamides as anti-inflammatory agents
WO2010059401A2 (en) * 2008-10-30 2010-05-27 Irm Llc Compounds that expand hematopoietic stem cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1963, ITAYA MOTOITI ET AL.: "Synthetic studies in benzimidazole series.", XP002676720, Database accession no. 1963:27248 *
DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1 April 2008 (2008-04-01), XP002676721, retrieved from STN Database accession no. 1011408-27-7 *
DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 18 April 2008 (2008-04-18), XP002676723, retrieved from STN Database accession no. 1015591-10-2 *
DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 26 June 2007 (2007-06-26), XP002676722, retrieved from STN Database accession no. 939242-05-4 *
YAKUGAKU ZASSHI, vol. 82, 1962, pages 634 - 639 *

Also Published As

Publication number Publication date
WO2012102937A2 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
WO2010059401A3 (en) Compounds that expand hematopoietic stem cells
WO2012102937A3 (en) Benz imidazole compounds that expand hematopoietic stem cells
MX2019014009A (en) Improved methods for manufacturing adoptive cell therapies.
EP2603227A4 (en) Improved hematopoietic stem and progenitor cell therapy
HK1217450A1 (en) Combined organ and hematopoietic cells for transplantation tolerance of grafts
WO2013005053A3 (en) Progenitor cells of mesodermal lineage
EP3122181A4 (en) Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells
WO2012012737A3 (en) Stable tregs and related materials and methods
BR112013002811A8 (en) simplified basic means for human pluripotent cell culture
WO2011139628A8 (en) Generation of anterior foregut endoderm from pluripotent cells
JO3266B1 (en) Silent Fc variants of anti-CD40 antibodies
WO2014153115A3 (en) Compositions and methods for reprogramming hematopoietic stem cell lineages
EP2558124A4 (en) Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2011163669A3 (en) Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
MX2020005525A (en) Therapies with lanthionine c-like protein 2 ligands and cells prepared therewith.
WO2012095743A3 (en) Adipose -derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases
GB2500161B (en) Enhancement of allogeneic hematopoietic stem cell transplantation
IN2014DN08964A (en)
MX2021003383A (en) Methods for differentiating mesenchymal stem cells.
MX363385B (en) Treatment of sickle cell disease and inflammatory conditions.
SI2913394T1 (en) Co-differentiation and activation of monocytes from allogeneic donors to provide pro-inflammatory dendritic cells
UA103206C2 (en) Compounds that expand hematopoietic stem cells
Gu et al. Experimental Study of Human Gingival Tissue-Derived Mesenchymal Stem Cells in Management of Chronic graft-versushost disease (GVHD)
TR201910211T4 (en) Compounds that increase hematopoietic stem cells.
UY32209A (en) "COMPOUNDS THAT EXPAND HEMATOPOIETIC MOTHER CELLS"

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12702366

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12702366

Country of ref document: EP

Kind code of ref document: A2